Integral Molecular, a company discovering antibodies against multipass membrane proteins, has launched fully optimised, high-affinity lead monoclonal antibodies against Claudin 18.2 (CLDN18.2), a structurally complex oncology target overexpressed on various solid tumours, it was reported on Tuesday.
The CLDN18.2 antibodies found using the firm's MPS antibody discovery platform are ready to progress towards preclinical studies and are completely humanised, unlike the Phase 3 clinical benchmark.
Integral Molecular showcased its CLDN18.2 MAbs at the virtual PEGS Europe (Protein & Antibody Engineering Summit) earlier this month. CLDN18.2 is expressed in multiple cancers, including lung, pancreatic and oesophageal cancers, but indicates limited expression in healthy adult tissue.
Ross Chambers, VP of Antibody Discovery, said, 'The structural complexity of CLDN18.2 and the widespread expression of closely related family members has made discovery of highly specific antibodies against CLDN18.2 challenging. Our exquisitely specific, picomolar affinity lead candidates show stronger binding than the most advanced clinical antibody and are a testament to the ability of our platform to yield antibodies against difficult targets.'
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study